BioPharmSignal logoBioPharmSignal

Biotech News

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

Lisata Therapeutics (LSTA)Lisata TherapeuticsCompany update

Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders Lisata’s Board of Directors and management continues to evaluate strategic alternatives to enhance stockholder value In order to reduce operating expenses and

Related news

LSTALisata Therapeutics2026-06-10 12:00 EST

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

FATEFate Therapeutics2026-07-09 12:30 EST

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

NRIXNurix Therapeutics2026-06-08 05:00 EST

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

CGEMCullinan Therapeutics, Inc.2026-06-06 09:15 EST

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

View all latest news

Lisata Therapeutics

Lisata Therapeutics is a precision oncology company focused on therapies designed to improve tumor penetration and enhance drug delivery into solid tumors. Its story is built around the idea that better access to tumors can improve the performance of other anti-cancer approaches.

Recent company news

LSTALisata Therapeutics2026-08-04 11:00 EST

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

LSTALisata Therapeutics2026-06-10 12:00 EST

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

LSTALisata Therapeutics2026-03-06 23:15 EST

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

LSTALisata Therapeutics2026-01-27 13:00 EST

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

LSTALisata Therapeutics2026-01-21 12:00 EST

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Stock data

Close
1.07 USD
Market cap
31.69M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States